Sofosbuvir price for sale 13701351540 Agent Sofosbuvir

Sofosbuvir raw materials and tablets:
Drug name: sofosbuvir, sofosbuvir
English name:
Trade name:
Code: -,
Chemical name: [(3R)(,-dioxo,-dihydropyrimidinyl)fluoro-hydroxymethyl-tetrahydro-furylmethoxy]-phosphorylamino}-isopropylpropionate
Molecular formula:
Molecular weight:
Dosage form specifications: yellow capsule-shaped film-coated tablets, with a concave pattern on one side and a pattern on the other side. Each piece.
Indications: Hepatitis C
Application Category: Chemical Drug 3+
Foreign Marketing Information: Approved for marketing on the year, month, and day. Approved for the market on the year, month, and day.
Market status: Prescription drugs
Original research company: Gilead Sciences Inc.
Mechanism of action: Nucleoside B polymerase inhibitor
Product features and marketing information:
Type C Hepatitis (hereinafter referred to as hepatitis C) has become a global public health problem. The number of people infected with hepatitis C worldwide has exceeded 100 million. There are about 30,000 new infections every year, and more than 30,000 people may die from liver cancer caused by hepatitis C. The hepatitis C infection rate in my country is about 3%, and there are about 10,000 people infected with hepatitis C, and the incidence rate has been on the rise in recent years.
br is a new generation of nucleic acid analogue inhibitors, which was approved on March 3 for the treatment of chronic hepatitis C virus infection. Also approved br in combination with ribavirin for the treatment of adult patients with chronic hepatitis C genotype and genotype 3 br in combination with pegylated interferon (-) and ribavirin for the treatment of genotype and genotype 3 chronic hepatitis C Treatment of treatment-naïve adults with hepatitis C.
brIt is the first effective and safe drug to treat certain types of infection without the need for concurrent use of interferon. The industry agrees that this drug is the most blockbuster drug approved in the past three years. Sales in three weeks after three years reached 100 million US dollars. According to analysts' predictions, its hepatitis C business, with BR as the main force, has annual sales of up to 100 million U.S. dollars, of which BR alone can account for 300 million U.S. dollars. It is optimistically estimated that br sales are expected to eventually exceed 100 million US dollars. In fact, according to Gilead Sciences' fiscal second quarter performance report, sales of hepatitis C star drugs continue to maintain a steady growth trend. The drug generated sales of . A staggering US$300 million.